Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.68 |
| ▸ | FNTB | P49356 | 5/20 | 0.68 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 15/20 | 0.64 |
| ▸ | STS | P08842 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7987822 | 0.99 | FNTA (0.67) | FNTAFNTBPGGT1BCYP19A1STS | |
| SCHEMBL3500619 | 0.81 | FNTA (1.00) | FNTAFNTBPGGT1B | |
| SCHEMBL3500598 | 0.81 | CYP19A1 (0.61) | FNTAFNTBPGGT1BCYP19A1STS | |
| Hydrochloric Acid SCHEMBL7971075 | 0.80 | FNTA (0.98) | FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL7987820 | 0.80 | CYP19A1 (0.60) | FNTAFNTBPGGT1BCYP19A1STS | |
| SCHEMBL306242 | 0.79 | CYP19A1 (1.00) | CYP19A1STSCA2 | |
| SCHEMBL3501291 | 0.76 | FNTA (0.67) | FNTAFNTBPGGT1BCYP19A1 | |
| SCHEMBL10172757 | 0.76 | CYP19A1 (1.00) | CYP19A1STS | |
| Hydrochloric Acid SCHEMBL7980502 | 0.76 | FNTA (0.66) | FNTAFNTBPGGT1BCYP19A1 | |
| SCHEMBL3499476 | 0.75 | FNTA (1.00) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744751-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-01-24 | — | — | EP | claimed |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-15 | — | — | US | claimed |
| WO-2005089502-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | claimed |
| EP-1021188-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-07-26 | — | — | EP | claimed |
| WO-1999017777-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-04-15 | — | — | WO | claimed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2010057028-A9 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | LINK MEDICINE CORPORATION (MA) | 2010-07-22 | — | — | US | disclosed |
| WO-2010057028-A2 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2155197-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | Link Medicine Corporation (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008112525-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | LINK MEDICINE CORPORATION (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-12-20 | — | — | US | disclosed |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005089502-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| US-6297239-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2000059930-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1021188-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999017777-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | FNTA 4/4885FNTB 19/4885PGGT1B 274/4885 |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | GAA, GBA1, MAN2B1 | FNTA 19/4885FNTB 24/4885PGGT1B 191/4885 |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | FNTA 24/4885FNTB 49/4885PGGT1B 2532/4885 |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | SNCA, PARK7, NLN | FNTA 12/4885FNTB 44/4885PGGT1B 1996/4885 |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | FNTA 1/4885FNTB 2/4885PGGT1B 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.